Abstract:Introduction: Approved angiogenesis inhibitors generally target certain growth factors or their receptors, which exist in both normal and cancerous cells; this results in suppression of cell-signaling pathways throughout the body and causes adverse effects. For this reason, there is a need for a new angiogenesis inhibitor that can specifically target the tumor vasculature. In our previous study, we revealed that doppel, a prion-like protein, was overexpressed specifically in the tumor vasculatures, but not in normal endothelium, and its expression enhanced blood vessel formation. To develop our new anti-angiogenic agent, we produced monoclonal antibodies which target doppel as the antigen. Methods: We evaluated whether the doppel antibody inhibits angiogenesis by a spheroid assay. We cultured human colonic tumor-associated endothelial cells (HCTEC) and collected the cells by a hanging drop method. After producing compact aggregates, the spheroids were collected and embedded into collagen-based 3D cultures. The culture media/growth factor/doppel antibody mixture was added to each well that contained 3D spheroid cultures. After 24 hours, the number of sprouts was counted and analyzed. Further, HCTECs were incubated with culture media, growth factor, and doppel antibodies for investigating the underlying mechanisms. Each well was lysed, and we conducted western blot and microarray experiments using the lysates. In addition, we injected fluorescent dye-conjugated doppel antibody into tumor xenograft mouse models and visualized the tumor-targeting efficacy using in vivo imaging system (IVIS). Results: In spheroid assays, we found that doppel antibody SNU-H01 and SNU-H02 inhibit angiogenesis (by 32% and 29%, respectively) compared to control. In anti-phosphorylation assays using western blot, the amount of phosphorylated VEGFR2 and phosphorylated FGFR1 was decreased in doppel antibody SNU-H01 and SNU-H02-treated groups. Also, when SNU-H02-treated lysate was added to the microarray kit, STAT5A and beta-catenin were inhibited. Inhibition of STAT5A may promote apoptosis and increase sensitivity to anticancer drugs, and inhibition of beta-catenin may further increase suppression of angiogenesis. In addition, doppel antibody SNU-H04 accumulates in the tumor significantly higher compared to IgG injected mouse group. Conclusion: Doppel antibodies in development, SNU-H01, -H02, -H03, -H04, will be screened and selected for their anti-angiogenic efficacy and favorable pharmacodynamic features. We hope that doppel antibody is expected to be a new and superior tumor vasculature-specific angiogenesis inhibitor that can overcome the limitations of existing anti-angiogenic agents. Citation Format: Ha Kyeong Lee, Ruby Maharjan, Yeojin Jeon, Jeong Uk Choi, Youngro Byun. Anti-doppel monoclonal antibody as a tumor endothelial cell-specific angiogenesis inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 339.

A Non-immunogenic Bivalent d -Protein Potently Inhibits Retinal Vascularization and Tumor Growth

Selectively Suppressing Tumor Angiogenesis for Targeted Breast Cancer Therapy by Genetically Engineered Phage.

Abstract 339: Anti-doppel monoclonal antibody as a tumor endothelial cell-specific angiogenesis inhibitor

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

Multivalent nanobodies with rationally optimized linker and valency for intravitreal VEGF neutralization

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect in Vivo

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy Via Blocking Vascular Endothelial Growth Factor Signaling.

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]

Suppression of Tumor Growth and Metastasis by a VEGFR-1 Antagonizing Peptide Identified from a Phage Display Library.

In Silico designed cell-penetrating anti-cancer peptide specifically inhibits VEGF-A expression

A Bioengineered Anti‐vegf Protein with High Affinity and High Concentration for Intravitreal Treatment of Wet Age‐related Macular Degeneration

Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis